Expertise in
19
conditions

Dr. Salma K. Jabbour

Radiation Oncology
Rutgers Health-Rwj Scleroderma Program
195 Little Albany St, 
New Brunswick, NJ 
Accepting New Patients
Expertise in
19
conditions
Rutgers Health-Rwj Scleroderma Program
195 Little Albany St, 
New Brunswick, NJ 

Overview

Salma Jabbour is a Radiation Oncologist in New Brunswick, New Jersey. Dr. Jabbour is highly rated in 19 conditions, according to our data. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Liver Embolization, and Pancreaticoduodenectomy. Dr. Jabbour is currently accepting new patients.

Her clinical research consists of co-authoring 233 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Radiation Oncology

Licenses

Radiology in NJ

Hospital Affiliations

Robert Wood Johnson University Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

RUTGERS HEALTH-RWJ SCLERODERMA PROGRAM
195 Little Albany St, New Brunswick, NJ 08901

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Enrollment Status: Suspended
Publish Date: February 12, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Avelumab, Peposertib
Study Phase: Phase 1/Phase 2
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: February 12, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Other, Radiation, Drug
Study Drug: Paclitaxel
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: January 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With Pembrolizumab
A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With Pembrolizumab
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2026
Intervention Type: Other, Drug, Radiation, Biological
Study Drugs: Capecitabine, Pembrolizumab
Study Phase: Phase 2
Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 16, 2025
Intervention Type: Radiation, Drug, Other, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 1
View 9 Less Clinical Trials

233 Total Publications

Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 13, 2026
Similar Doctors
Andreas Rimner
Expertise in
16
conditions
Dr. Andreas Rimner
Radiation Oncology
Expertise in
16
conditions
Dr. Andreas Rimner
Radiation Oncology

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (31.8 miles away)
212-639-2000
Languages Spoken:
English

Andreas Rimner is a Radiation Oncologist in New York, New York. Dr. Rimner is highly rated in 16 conditions, according to our data. His top areas of expertise are Lung Cancer, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Tissue Biopsy, and Thymectomy.

Expertise in
54
conditions
Dr. Kaled Alektiar
Radiation Oncology
Expertise in
54
conditions
Dr. Kaled Alektiar
Radiation Oncology

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (31.8 miles away)
646-582-9491
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kaled Alektiar is a Radiation Oncologist in New York, New York. Dr. Alektiar is highly rated in 54 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Adult Soft Tissue Sarcoma, Fibrosarcoma, Cervical Cancer, and Lymphadenectomy. Dr. Alektiar is currently accepting new patients.

Expertise in
17
conditions
Dr. Joachim Yahalom
Radiation Oncology
Expertise in
17
conditions
Dr. Joachim Yahalom
Radiation Oncology

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (31.8 miles away)
929-459-8263
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joachim Yahalom is a Radiation Oncologist in New York, New York. Dr. Yahalom is highly rated in 17 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma (MZL), Plasmacytoma, and Tissue Biopsy. Dr. Yahalom is currently accepting new patients.

Frequently Asked Questions about Dr. Salma K. Jabbour

How do I make an appointment with Dr. Salma K. Jabbour?

You can book an appointment with Dr. Salma K. Jabbour by calling their office at 732-253-3939. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Salma K. Jabbour a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Salma K. Jabbour is classified as an Elite expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Salma K. Jabbour specialize in?

While Dr. Salma K. Jabbour is a Radiation Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Salma K. Jabbour participate in research or clinical trials?

Yes. Dr. Salma K. Jabbour has published 233 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Salma K. Jabbour's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Salma K. Jabbour accept my insurance?

Dr. Salma K. Jabbour accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 732-253-3939 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jabbour's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 11 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile